ArticleCell proliferation2026
ITGA5 as a Dual Regulator of Epithelial-Mesenchymal Transition and Epithelial Cell Anoikis Resistance: Functional Validation and Drug Prediction.
Article in Cell proliferation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Airway remodelling is a major contributor to persistent airflow limitation and irreversible lung function impairment in asthma, with epithelial-mesenchymal transition (EMT) serving as a key driver. However, the molecular mechanisms controlling EMT in asthma epithelium remain incompletely elucidated. This study reported that integrin α5 (ITGA5) was markedly upregulated in asthma patients, house dust mite (HDM)-sensitised asthma mice, and transforming growth factor beta 1 (TGF-β1)-induced in vitro EMT models. Elevated ITGA5 expression correlated positively with reduced lung function, asthma severity and higher levels of EMT regulators (Fibronectin, N-cadherin, Vimentin) and was functionally linked to anoikis resistance. In TGF-β1-induced bronchial epithelial cells exhibiting anoikis resistance, quantitative proteomics revealed that ITGA5 promoted mesenchymal transition via the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway and negatively regulated anoikis. ITGA5 directly bound to PI3K in vitro, and ITGA5 knockdown reversed TGF-β1-induced EMT, inhibited the activation of the PI3K/Akt pro-survival pathway, and restored anoikis sensitivity. According to molecular docking, molecular dynamics simulation and in vivo and in vitro pharmacological assays, resveratrol (Res) and M200 were found to be potential ITGA5 inhibitors that successfully reduced EMT and anoikis resistance, thereby attenuating airway remodelling in asthma mice and offering promising drug candidates for ITGA5-targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.